ClinicalTrials.gg
CompletedNCT05780749Updated May 2, 2025

A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

An interventional study of DDI-IBS-001 and DDDI-IBS-001 placebo in Irritable Bowel Syndrome, sponsored by Biokuris s.a.. Completed at 11 sites in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Biokuris s.a. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Irritable Bowel Syndrome with a site in Belgium — 12 open to participants now, 13 under way, 3 of them phase 3. Irritable Bowel Syndrome · Belgium.

Enrollment
12th of 29
116 · median 90
Started
2023
with 5 others
No phase
16 of 32
7 open now
Registered
22nd of 32
by date
Lead sponsor
2 of 32
Biokuris s.a.

Among the 32 studies in Irritable Bowel Syndrome with a site in Belgium, this one is the 12th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 with no phase, and was the 22nd registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

12 of the 32 studies in Irritable Bowel Syndrome with a site in Belgium are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Irritable Bowel Syndrome with a site in Belgium, or all of them as a file.
02

Study summary

Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal condition that affects approximately 10-20% of adults in Western countries. IBS is a disorder with chronic or recurrent colonic symptoms without a clear-cut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. Over 80% of individuals with IBS report food-related symptoms leading in the 70% of these patients to self-imposed food restrictions and/or modifications of their diet. These spontaneous unsupervised dietary modifications are associated with maladaptive eating patterns and unnecessary self-restricted diets, which could result in nutritional deficiencies.

BiOkuris product DDI-IBS-001 is a food multicomponents product based on BiOkuris proprietary chitin-glucan complex. The objectives of the VITABIOTIC study is to confirm the effectiveness of the DDI-IBS-001 product in improving global symptoms, abdominal pain, stool consistency, quality of life, anxiety and depression in IBS patients and to confirm the product's safety.

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • IBS
  • chitin-glucan
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult females and males, aged 18-75 years,
  2. Diagnosis of IBS at least 6 months prior to study entry,
  3. Confirmed IBS according to Rome-IV criteria (as determined by investigator),
  4. Patient having either constipation (IBS-C), diarrhoea (IBS-D) or alternance of constipation/diarrhoea (IBS-M),
  5. Possession of a digital device (i.e., smartphone or tablet),
  6. Patient who read, understood, and signed the form (ICF),
  7. Patient willing to adhere to the study visit schedule and capable to understand and comply with protocol requirements and product intake,
  8. Male, or female patient of , who agrees to use acceptable methods throughout the study period.

    As assessed at the end of the run-in period, week 2 :

  9. Patient with a baseline score for abdominal pain ≥ 2 and \< 6 assessed on a 7-point Lickert scale
  10. Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (≥75% completion)

Exclusion criteria

Exclusion Criteria:

  1. Severe gastrointestinal pathologies other than IBS, including: ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, bowel resection, auto-immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Graves' disease), bariatric surgery, acute or chronic diarrhoea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition,
  2. Metabolic disorders affecting intestinal transit function or nutrient absorption including uncontrolled diabetes and uncontrolled dysthyroidism,
  3. Patients experiencing complications of abdominal radiotherapy,
  4. Surgical operations to the mouth or gastrointestinal tract within 4 weeks prior to study entry, or planned during the study; appendectomy within 6 months prior to study entry,
  5. Galactose intolerance ,
  6. Use of opioids or narcotic analgesics within 6 weeks prior to week 0,
  7. Systemic antibiotic treatment in progress or prescribed less than 4 weeks prior to study entry,
  8. Use of products marketed as or rich in prebiotics, probiotics, or symbiotics (e.g., kefir, probiotic yogurt, baker's yeast, etc.) less than 2 weeks prior to week 0,
  9. Use of laxatives, antibloating agents, antidiarrheal medication, antispasmodics, anxiolytics, antidepressants, analgesics, and non-steroidals anti-inflammatory drugs if started less than 2 months prior to week 0 . These medications are authorized if consumed for longer than 2 months before week 0 and maintained at a stable dosage for the entire study duration,,
  10. Diets including low-FODMAP, KETO/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high-protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calory), or vegan diets if started less than 2 months prior or stopped less than 1 month prior to week 0. These diets are authorized if followed for longer than 2 months before week 0 and maintained for the entire study duration,,
  11. Excessive alcohol consumption (more than 10 units per week) and/or drug abuse,
  12. Pregnancy and lactation, or plan to become pregnant during the study period,
  13. Participation in other studies involving or marketed products concomitantly or less than 3 months prior to study entry,
  14. Known to any of the ingredients or of the investigational products,
  15. Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.

    As assessed at the end of the run-in period, week 2 :

  16. Use of opioids or narcotic analgesics during the run-in period (between week 0 and week 1),
  17. Systemic antibiotic treatment in progress or prescribed during the run-in period (between week 0 and week 1),
  18. Deviation from lifestyle and dietary recommendations to be followed during the study (between week 0 and week 1).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Active arm - DDI-IBS-001

    Dietary Supplement: DDI-IBS-001

  • Placebo comparator
    Placebo arm

    Other: DDDI-IBS-001 placebo

Interventions

  • Dietary supplementDDI-IBS-001

    The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.

  • OtherDDDI-IBS-001 placebo

    The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.

06

What researchers measure

Primary outcomes

  1. Symptoms global assessment of relief (SGA) responder rate

    The primary outcome is the subjective global assessment (SGA) of relief responder rate at Week 8. Patients with an SGA of relief score of 3 points or less each week will be considered weekly responders. Patients who respond weekly for at least 50% of assessments after 2 weeks of Biokuris food supplement administration until V3 will be considered overall responders.

    Time frame: Week 10 (8 weeks after run-in period)

Secondary outcomes

  1. Weekly SGA responder rate

    The SGA of relief weekly responder rate after 8 weeks of Biokuris food supplement administration. Patients with an SGA of relief score of 3 points or less each week will be considered weekly responders.

    Time frame: weekly from week 2 to week 14

  2. Individual symptoms

    Weekly change from baseline in mean 7-point Likert scale for each of the symptoms: abdominal pain, abdominal bloating, flatulence, dyschezia, pain during evacuation. Patients will score the intensity of each symptom individually from 1 (none) to 7 (very severe). Incidence of responders.

    Time frame: weekly from week 2 to week 14

  3. stool consistency

    Change in the weekly mean number of normal stool consistency, evaluated with the BSS. Stool consistency (BSS score) will be described for each week until V4. The change in the weekly average number of normal stool consistency will be calculated between week 2 (baseline), and each week of treatment

    Time frame: weekly from week 2 to week 14

  4. number of evacuation per day

    Change in the weekly mean number of evacuations per day. The mean daily number of bowel movements will be calculated for each week until week 14. The change in the weekly average number of evacuations will be calculated between week 2 (baseline), and each week of treatment, until week 14. A stratification will be performed according to weekly mean numbers registered at week 2.

    Time frame: weekly from week 2 to week 14

  5. IBS-QoL

    Absolute and relative change of IBS-QoL (Quality of Life) score. An analysis for each of the 8 domains of the validated questionnaire will be performed.

    Time frame: Week 0, week 4, week 8, week 10, week 14

  6. Anxiety & Depression

    Monthly change from baseline in Hospitalization Anxiety and Depression Scale (HADS) score. It is divided into an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both containing 7 intermingled items, and are scored separately. For both scales, scores of less than 7 indicate non-cases, and between 8-10 mild, 11-14 moderate and 15-21 severe symptomatology.

    Time frame: Week 0, week 4, week 8, week 10, week 14

  7. Adverse events

    occurrence and severity of adverse events

    Time frame: Week 0, week 2, week 4, week 8, week 10, week 14

07

Study locations

11 sites
  • Centre Hospitalier EpiCURA
    Ath, 7800, Belgium
  • AZ Sint-Jan
    Brugge, 8000, Belgium
  • AZ Sint-Lucas
    Brugge, 8310, Belgium
  • CUB Hôpital Erasme
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • AZ Sint-Lucas
    Gent, 9000, Belgium
  • UZ Brussel
    Jette, 1090, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Liege
    Liege, 4000, Belgium
  • Clinique CHC Mont-Legia
    Liege, 4000, Belgium
  • Centre Hospitalier du Bois de l'Abbaye
    Seraing, 4100, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 14 months is close to that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Mar 23, 2023
StartActual
Nov 23, 2023
Primary completionActual
Feb 2, 2025
CompletionActual
Feb 2, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05780749
Lead sponsor
Biokuris s.a.
Responsible party
Sponsor
First posted
Mar 23, 2023
Start date
Nov 23, 2023
Primary completion
Feb 2, 2025
Completion
Feb 2, 2025
Last update
May 2, 2025

Study contacts

Jan Tack, Professor
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion